AMRI Expands; Richter–Helm Starts Construction of $84-M Biomfg Facility
The latest from CDMOs, CMOs, and suppliers featuring AMRI, Richter–Helm, and Cellares Corporation.
Richter–Helm Starts Construction of $84-M Biomanufacturing Facility
Richter–Helm, a biologics CDMO based in Hamburg, Germany, has started construction for a new multi-product biological manufacturing facility in Bovenau, Germany. The facility is expected to begin full-scale operations and manufacturing by the end of 2023.
Richter–Helm and its parent companies, Gedeon Richter, a Budapest, Hungary-based bio/pharmaceutical company, and Helm AG, a Hamburg, Germany-based chemicals/fine chemicals distributor, will invest approximately EUR 70 million ($84 million) to triple the current production capacity of Richter–Helm and expand its existing warehouse, laboratory, and administration buildings.
Richter–Helm currently operates a development facility and two cGMP manufacturing facilities for microbial production in Hannover and Bovenau, Germany, with bioreactor capacities of up to 1,500 liters. The Bovenau expansion covers installment of two additional production trains with bioreactor capacities of 300 liters and 1,500 liters. The production site will reach a total area of about 10,000 m² and includes all necessary utilities and infrastructure, such as quality-control labs, warehousing, and technical areas.
Cellares Raises $82 M To Expand Cell-Therapy Mfg Platform
Cellares, a South San Francisco, California-based life-sciences technology company that automates cell-therapy manufacturing, has secured $82 million to expand its cell-therapy manufacturing capabilities.
This latest funding will accelerate development of Cell Shuttle, Cellares’ modular and automated platform for the production of individualized cell therapies. It consists of hardware, software, robotics, and consumables and is capable of producing 10 patient doses simultaneously
The $82 million was secured in a Series B round to bring total funding to $100 million to date (as reported on May 5, 2021).
Source: Cellares Corporation
AMRI Expands To Service Orphan, Rare Disease Products
Albany Molecular Research, Inc. (AMRI), a contract research, development and manufacturing organization, has made targeted investments globally to expand its scale and compound-handling capabilities for orphan and rare-disease products at its facilities in Albany, New York; Grafton, Wisconsin; and Glasgow, Scotland. The company also made additions to the teams that support these products.
The expansion includes additional suites in at its site in Albany that are designed to manufacture batch sizes of 10–15 kilograms. AMRI’s Grafton facility has expanded its hydrogenation, filtering, drying, and analytical capabilities. It has added liquid chromatography–mass spectrometry and gas chromatography-mass spectrometry instruments in expanded laboratory space and recruited additional analytical experts. AMRI’s Glasgow facility is an integrated single site with formulation development and clinical sterile drug-product manufacture capabilities, which supports formulation and process development and GMP manufacture of orphan drug products.